4D Molecular Therapeutics (FDMT) CFO receives 480,000-share option grant

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. reported an equity award for its Chief Financial Officer. The officer received a stock option covering 480,000 shares of common stock at an exercise price of $10.51 per share, dated 12/09/2025, with the option expiring on 12/08/2035.

According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the November 17, 2025 vesting commencement date. The remaining shares vest in 36 equal monthly installments so that the option is fully vested on the fourth anniversary of that date, provided the officer continues as a service provider to the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Humer Kristian

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	480,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 480,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humer Kristian

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.51	12/09/2025		A		480,000		(1)	12/08/2035	Common Stock	480,000	$0	480,000	D

Explanation of Responses:

1. 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily as Attorney-in-Fact for Kristian Humer	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 4D Molecular Therapeutics (FDMT) report?

The company reported that its Chief Financial Officer acquired a stock option to purchase 480,000 shares of 4D Molecular Therapeutics common stock.

What are the key terms of the FDMT CFO stock option grant?

The option covers 480,000 shares of common stock at an exercise price of $10.51 per share, was granted on 12/09/2025, and expires on 12/08/2035.

How do the CFO’s 4D Molecular Therapeutics (FDMT) options vest?

25% of the shares vest on the first anniversary of the November 17, 2025 vesting commencement date. The remaining shares vest in 36 equal monthly installments so that all shares are fully vested on the fourth anniversary, subject to continued service.

Who is the reporting person in this FDMT insider transaction?

The reporting person is the company’s Chief Financial Officer, identified in the filing as represented by Scott Bizily acting as attorney-in-fact for Kristian Humer.

Is the CFO’s stock option in the FDMT filing held directly or indirectly?

The filing shows 480,000 derivative securities (stock options) beneficially owned with an ownership form marked as Direct (D).